Allworth Financial LP Erasca, Inc. Transaction History

Allworth Financial LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 25, 2024	BUY	$1.67 - $2.55 $1,604 - $2,450	961 Added 331.38%	1,251 $2,000
Q4 2023 Jan 24, 2024	SELL	$1.67 - $2.49 $280 - $418	-168 Reduced 36.68%	290 $0
Q3 2023 Oct 31, 2023	SELL	$1.97 - $2.91 $1,185 - $1,751	-602 Reduced 56.79%	458 $0
Q2 2023 Jul 18, 2023	BUY	$2.57 - $3.3 $2,382 - $3,059	927 Added 696.99%	1,060 $2,000
Q1 2023 Apr 18, 2023	BUY	$2.74 - $4.44 $364 - $590	133 New	133 $0

140

229M

28.7K

117K

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $310M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

Stay updated on Allworth Financial LP with notifications on news.